# Master Project Checklist

## Lithium Orotate for Cognitive Protection Study

**Protocol**: LAHAI-LI-2026-001
**Last Updated**: February 5, 2026
**Status**: Phase 1 Preparation

---

## Project Dashboard

| Milestone | Target Date | Status |
|-----------|-------------|--------|
| Literature Review | Feb 2026 | ‚úÖ Complete |
| Protocol Development | Feb 2026 | ‚úÖ Complete |
| IRB Submission | Mar 2026 | ‚è≥ Pending |
| IRB Approval | Apr-May 2026 | ‚è≥ Pending |
| First Participant Enrolled | Jun 2026 | ‚è≥ Pending |
| Phase 1 Completion | Jun 2027 | ‚è≥ Pending |

---

## Section 1: Foundation & Team

### 1.1 Team Assembly

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òëÔ∏è Identify Principal Investigators | Fabio | Feb 2026 | ‚úÖ Done |
| ‚òê Confirm Claudia Correa commitment (Clinical Lead) | Claudia | Feb 2026 | ‚è≥ |
| ‚òê Confirm Dr. Cohen commitment (Medical Director) | Phil | Feb 2026 | ‚è≥ |
| ‚òê Confirm Robert Deeble commitment (Research Oversight) | Robert | Feb 2026 | ‚è≥ |
| ‚òëÔ∏è Define roles and responsibilities in writing | Fabio | Feb 2026 | ‚úÖ Done |
| ‚òê Execute team commitment letters | All PIs | Mar 2026 | ‚è≥ Drafts Ready |

### 1.2 Organizational Infrastructure

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Confirm Lahai Health as institutional sponsor | Lahai Board | Feb 2026 | ‚è≥ |
| ‚òê Establish research email addresses | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Set up secure document storage (HIPAA-compliant) | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Create project communication channels | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Obtain Lahai Health EIN for grants | Lahai | Feb 2026 | ‚è≥ |

---

## Section 2: Documentation

### 2.1 Core Protocol Documents

| Document | Location | Status |
|----------|----------|--------|
| ‚òëÔ∏è Research Protocol | [research/RESEARCH-PROTOCOL.md](research/RESEARCH-PROTOCOL.md) | ‚úÖ Complete |
| ‚òëÔ∏è Study Goals | [docs/STUDY-GOALS.md](docs/STUDY-GOALS.md) | ‚úÖ Complete |
| ‚òëÔ∏è IRB Protocol | [clinical/IRB-PROTOCOL.md](clinical/IRB-PROTOCOL.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è IRB Selection Guide | [clinical/IRB-SELECTION-GUIDE.md](clinical/IRB-SELECTION-GUIDE.md) | ‚ö†Ô∏è Decision Required |
| ‚òëÔ∏è Informed Consent (English) | [clinical/INFORMED-CONSENT.md](clinical/INFORMED-CONSENT.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è Informed Consent (Spanish) | [clinical/INFORMED-CONSENT-ES.md](clinical/INFORMED-CONSENT-ES.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è Informed Consent (Portuguese) | [clinical/INFORMED-CONSENT-PT.md](clinical/INFORMED-CONSENT-PT.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è Case Report Forms | [clinical/CASE-REPORT-FORMS.md](clinical/CASE-REPORT-FORMS.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è Screening Checklist | [clinical/SCREENING-CHECKLIST.md](clinical/SCREENING-CHECKLIST.md) | ‚úÖ Draft Complete |
| ‚òëÔ∏è PI Commitment Letters | [clinical/PI-COMMITMENT-LETTERS.md](clinical/PI-COMMITMENT-LETTERS.md) | ‚úÖ Drafts Ready |

### 2.2 Literature & Evidence

| Document | Location | Status |
|----------|----------|--------|
| ‚òëÔ∏è Literature Matrix | [literature/LITERATURE-MATRIX.md](literature/LITERATURE-MATRIX.md) | ‚úÖ Complete |
| ‚òëÔ∏è Primary Sources | [literature/PRIMARY-SOURCES.md](literature/PRIMARY-SOURCES.md) | ‚úÖ Complete |
| ‚òëÔ∏è Clinical Trials | [literature/CLINICAL-TRIALS.md](literature/CLINICAL-TRIALS.md) | ‚úÖ Complete |
| ‚òëÔ∏è Epidemiological Studies | [literature/EPIDEMIOLOGICAL-STUDIES.md](literature/EPIDEMIOLOGICAL-STUDIES.md) | ‚úÖ Complete |
| ‚òëÔ∏è Evidence Synthesis | [analysis/EVIDENCE-SYNTHESIS.md](analysis/EVIDENCE-SYNTHESIS.md) | ‚úÖ Complete |
| ‚òëÔ∏è Hypothesis Evaluation | [analysis/HYPOTHESIS-EVALUATION.md](analysis/HYPOTHESIS-EVALUATION.md) | ‚úÖ Complete |

### 2.3 Stakeholder Materials

| Document | Location | Status |
|----------|----------|--------|
| ‚òëÔ∏è Executive Summary | [docs/EXECUTIVE-SUMMARY.md](docs/EXECUTIVE-SUMMARY.md) | ‚úÖ Complete |
| ‚òëÔ∏è Clinical Implications | [docs/CLINICAL-IMPLICATIONS.md](docs/CLINICAL-IMPLICATIONS.md) | ‚úÖ Complete |
| ‚òëÔ∏è Future Research | [docs/FUTURE-RESEARCH.md](docs/FUTURE-RESEARCH.md) | ‚úÖ Complete |
| ‚òê Funding Strategy | [clinical/FUNDING-STRATEGY.md](clinical/FUNDING-STRATEGY.md) | ‚è≥ In Progress |
| ‚òê Investor/Funder Pitch Deck | TBD | ‚è≥ Pending |

### 2.4 Documents Requiring Finalization

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Fill in PI contact information in all documents | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Add IRB name and contact in consent form | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Select supplement brand/source | Phil | Feb 2026 | ‚è≥ |
| ‚òê Medical Director review of IRB protocol | Phil | Feb 2026 | ‚è≥ |
| ‚òê Legal review of consent form | Lahai | Mar 2026 | ‚è≥ |

---

## Section 3: Regulatory & Ethics

### 3.1 IRB Preparation

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê **SELECT EXTERNAL IRB** (Lahai has no internal IRB) | Fabio/Phil | Feb 2026 | ‚ö†Ô∏è CRITICAL |
| ‚òê Budget IRB fees ($2,000-3,000) in funding requests | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Complete IRB registration if needed | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Prepare IRB application package | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Complete PI CITI training (human subjects) | All PIs | Mar 2026 | ‚è≥ |
| ‚òê Submit IRB application | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Respond to IRB modifications | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Receive IRB approval | IRB | Apr-May 2026 | ‚è≥ |

### 3.2 IRB Options to Evaluate

> ‚ö†Ô∏è **IMPORTANT**: Lahai Health does not have an internal IRB. An external IRB must be selected and budgeted before the study can proceed. This is a **critical path item**.
>
> üìÑ **See**: [IRB-SELECTION-GUIDE.md](IRB-SELECTION-GUIDE.md) for detailed comparison, costs, timeline, and recommendation.

#### Recommended: Commercial/Independent IRBs

For a Phase 1 feasibility study with supplements (not drugs), commercial IRBs offer the fastest path:

| IRB | Estimated Cost | Timeline | Notes |
|-----|----------------|----------|-------|
| [Sterling IRB](https://www.sterlingirb.com/) | $1,500-3,000 | 2-3 weeks | **Recommended** - Budget-friendly, experienced with supplement studies |
| [Solutions IRB](https://www.solutionsirb.com/) | $1,000-2,500 | 2-3 weeks | Budget-friendly option |
| [Advarra](https://www.advarra.com/) | $2,000-4,000 | 2-4 weeks | Common for academic spinoffs |
| [WCG IRB](https://www.wcgirb.com/) | $2,500-5,000 | 2-4 weeks | Largest commercial IRB |

#### Alternative: Academic Partnership

| Option | Approach | Timeline | Notes |
|--------|----------|----------|-------|
| University of Washington | Partner with faculty co-investigator | 4-8 weeks | Adds academic credibility, lower cost |
| Seattle Pacific University | Affiliation agreement | 4-6 weeks | Local option |

#### Other Options to Explore

| Option | Notes |
|--------|-------|
| **Verdant Health Commission** | As a hospital district, may have IRB access or partnerships |
| **Swedish/Providence Health** | Sometimes review community studies |
| **Washington State WIRB** | State relationships with Western IRB |

#### Budget Recommendation

- Add **$2,000-3,000** to Phase 1 budget for IRB fees
- Add **4-6 weeks** to project timeline for IRB review and approval
- Total IRB timeline: Submit March 2026 ‚Üí Approval April-May 2026

### 3.3 Regulatory Compliance

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Confirm study qualifies as exempt/expedited | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Determine IND requirements (likely not needed) | Phil | Feb 2026 | ‚è≥ |
| ‚òê Register on ClinicalTrials.gov (if required) | Fabio | Post-IRB | ‚è≥ |
| ‚òê Establish adverse event reporting procedures | Phil | Mar 2026 | ‚è≥ |
| ‚òê Create protocol deviation log template | Fabio | Mar 2026 | ‚è≥ |

---

## Section 4: Operational Setup

### 4.1 Clinical Site Preparation

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Identify primary clinical site (Claudia's practice) | Claudia | Feb 2026 | ‚è≥ |
| ‚òê Designate private space for assessments | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Establish referral pathway from other clinicians | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Create participant scheduling system | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Set up secure participant contact list | Fabio | Mar 2026 | ‚è≥ |

### 4.2 Supply Chain

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Research lithium orotate suppliers | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Evaluate product quality/purity certifications | Phil | Mar 2026 | ‚è≥ |
| ‚òê Select supplier and document lot numbers | Phil | Mar 2026 | ‚è≥ |
| ‚òê Order initial 6-month supply | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Establish supplement storage protocol | Claudia | Apr 2026 | ‚è≥ |

### 4.3 Laboratory Partnership

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Identify lab partner (Quest/LabCorp/other) | Phil | Mar 2026 | ‚è≥ |
| ‚òê Negotiate research pricing if possible | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Establish lab order workflow | Phil | Apr 2026 | ‚è≥ |
| ‚òê Confirm patient insurance coverage options | Claudia | Apr 2026 | ‚è≥ |

### 4.4 Cognitive Assessment Setup

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Obtain MoCA license/certification | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Procure MMSE materials | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Obtain Trail Making Test forms | Claudia | Mar 2026 | ‚è≥ |
| ‚òê Create scoring templates | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Train assessor(s) on standardized administration | Claudia | Apr 2026 | ‚è≥ |

---

## Section 5: Data Management

### 5.1 Data Infrastructure

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Select data management platform (REDCap preferred) | Fabio | Mar 2026 | ‚è≥ |
| ‚òê Build electronic CRFs in platform | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Test data entry workflow | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Create data dictionary | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Establish backup procedures | Fabio | Apr 2026 | ‚è≥ |

### 5.2 Data Quality

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Define data validation rules | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Create query resolution workflow | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Plan interim data review schedule | All PIs | Apr 2026 | ‚è≥ |

---

## Section 6: Funding & Budget

### 6.1 Budget Development

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Complete Phase 1 budget estimate | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Identify funding sources | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Create funding strategy document | Fabio | Feb 2026 | ‚è≥ |
| ‚òê Determine Lahai Health contribution | Lahai Board | Mar 2026 | ‚è≥ |
| ‚òê Approach Verdant for sponsorship | Fabio | Mar 2026 | ‚è≥ |

### 6.2 Grant Applications

| Task | Owner | Due | Deadline | Status |
|------|-------|-----|----------|--------|
| ‚òê Research applicable NIH mechanisms | Fabio | Mar 2026 | Varies | ‚è≥ |
| ‚òê Identify foundation funding opportunities | Fabio | Mar 2026 | Varies | ‚è≥ |
| ‚òê Prepare R21 exploratory grant (if applicable) | Fabio | Q3 2026 | Oct 2026 | ‚è≥ |
| ‚òê Submit Alzheimer's Drug Discovery Foundation LOI | Fabio | Q2 2026 | Rolling | ‚è≥ |

---

## Section 7: Recruitment & Enrollment

### 7.1 Pre-Enrollment Preparation

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Develop participant identification strategy | Claudia | Apr 2026 | ‚è≥ |
| ‚òê Create recruitment script for existing clients | Claudia | Apr 2026 | ‚è≥ |
| ‚òê Develop educational materials for potential participants | Fabio | Apr 2026 | ‚è≥ |
| ‚òê Set recruitment targets (monthly) | Claudia | May 2026 | ‚è≥ |

### 7.2 Enrollment Tracking

| Milestone | Target N | Target Date | Actual |
|-----------|----------|-------------|--------|
| First participant enrolled | 1 | Jun 2026 | ‚è≥ |
| 25% enrollment (N=5-8) | 5-8 | Jul 2026 | ‚è≥ |
| 50% enrollment (N=10-15) | 10-15 | Aug 2026 | ‚è≥ |
| Full enrollment (N=20-30) | 20-30 | Oct 2026 | ‚è≥ |

---

## Section 8: Study Conduct

### 8.1 Active Trial Monitoring

| Task | Frequency | Owner |
|------|-----------|-------|
| ‚òê Adverse event review | Weekly | Phil |
| ‚òê Enrollment progress check | Weekly | Claudia |
| ‚òê Data entry verification | Bi-weekly | Fabio |
| ‚òê Protocol compliance audit | Monthly | All PIs |
| ‚òê Team meeting | Bi-weekly | All PIs |

### 8.2 Safety Monitoring

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Establish stopping rules | Phil | Apr 2026 | ‚è≥ |
| ‚òê Define SAE reporting workflow | Phil | Apr 2026 | ‚è≥ |
| ‚òê Create DSMB if required (likely not for pilot) | Phil | Apr 2026 | ‚è≥ |

---

## Section 9: Analysis & Reporting

### 9.1 Interim Analysis

| Timepoint | N Expected | Analysis Focus | Target Date |
|-----------|------------|-----------------|-------------|
| 3-month | 10-15 | Safety, tolerability | Q4 2026 |
| 6-month | 20-30 | Safety, preliminary efficacy | Q1 2027 |
| 12-month | 15-25 | Full analysis | Q2-Q3 2027 |

### 9.2 Final Reporting

| Task | Owner | Due | Status |
|------|-------|-----|--------|
| ‚òê Develop statistical analysis plan | Fabio | Q1 2027 | ‚è≥ |
| ‚òê Conduct final analysis | Fabio | Q3 2027 | ‚è≥ |
| ‚òê Prepare clinical study report | All PIs | Q3 2027 | ‚è≥ |
| ‚òê Draft manuscript | All PIs | Q4 2027 | ‚è≥ |
| ‚òê Submit for peer review | All PIs | Q4 2027 | ‚è≥ |

---

## Section 10: External Monitoring

### 10.1 Literature & Field Updates

| Task | Frequency | Owner |
|------|-----------|-------|
| ‚òê Monitor LATTICE trial results | Monthly | Fabio |
| ‚òê Watch Yankner orotate trial registration | Monthly | Fabio |
| ‚òê Review new lithium/AD publications | Monthly | Fabio |
| ‚òê Update evidence synthesis as needed | Quarterly | Fabio |

### 10.2 Key External Milestones to Track

| Event | Expected | Impact on Our Study |
|-------|----------|---------------------|
| LATTICE results publication | 2026 | Validates approach |
| Yankner orotate trial registration | 2026 | May inform dosing |
| FDA guidance on lithium for AD | TBD | Regulatory pathway |

---

## Critical Path Summary

### Must Complete Before IRB Submission (Mar 2026)

- [ ] PI commitments confirmed
- [ ] All clinical documents finalized (contact info filled)
- [ ] CITI training completed
- [ ] IRB selected
- [ ] Medical Director protocol review

### Must Complete Before First Enrollment (Jun 2026)

- [ ] IRB approval received
- [ ] Clinical site prepared
- [ ] Supplement supply secured
- [ ] Lab partnership established
- [ ] Data management system ready
- [ ] Cognitive assessment materials ready
- [ ] Assessor training completed

---

## Notes & Decisions Log

| Date | Decision/Note | Made By |
|------|--------------|---------|
| Feb 5, 2026 | Project initiated, documentation framework complete | Fabio |
| | | |
| | | |

---

*Master Checklist v1.0 ‚Äî February 5, 2026*
*Review and update weekly during active planning*
